Navigation Links
Hepatitis in Biological Technology

Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University

... licensed the exclusive worldwide rights to novel hepatitis C Virus (HCV) technology from Stanford ... future cocktails for HCV therapy." About hepatitis C Virus Infections from HCV have reached ... agents against novel targets for the treatment of hepatitis virus infections. Eiger's pipeline includes ...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

... with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance of the protocol has been ... used in combination in a Phase II trial to treat hepatitis C patients. This trial incorporates several ... Status from the FDA for the treatment of chronic hepatitis C. About Anadys Anadys ...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

... developing novel medicines for the treatment of hepatitis C, today reported its financial results and ... development of ANA598 as a treatment for chronic hepatitis C," said Steve Worland, Ph.D., President and CEO ... Phase I clinical trial for the treatment of hepatitis C. During the second quarter of 2008, ANA773 ...

Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results

... developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which ... polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the ...

Schering-Plough Reports Financial Results for 2009 Second Quarter

... boceprevir, a protease inhibitor in Phase III for hepatitis C; and BRIDION (sugammadex), an innovative agent ... U.S. and Japan. Sales of PEGINTRON for hepatitis C decreased 6 percent to $215 million in the 2009 ... SPRINT-1 study showing that boceprevir, an oral hepatitis C protease inhibitor, in combination with ...

Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)

... with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., June 19 ... patients with genotypes 2 and 3 chronic hepatitis C. Albuferon is being developed by HGS and ... 170 million people worldwide are infected with hepatitis C virus, including nearly four million in the ...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

... Approximately 50% of patients with chronic hepatitis C fail to respond to their initial course of ... by visiting www.infergen.com . About hepatitis C hepatitis means inflammation of the ....

Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program

... level to the state level which treats chronic hepatitis B, a condition which affects 10% of the ... success from its flagship Xin Ao Xin Oleanholic hepatitis B product to create a diversified product base addressing multiple indications. hepatitis B affects 10% of the Chinese population. This ...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

... in particular a proposed Phase II study in hepatitis C patients of ANA598 in combination with ... data from current cohorts in ongoing studies in hepatitis C and oncology, Anadys intends to manage the ... is preparing for the first Phase II trial in hepatitis C patients of ANA598 in combination with ...

Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study

... is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon. ... ribavirin as a cornerstone in the treatment of hepatitis C, but with the advantage of less anemia," said ... the potential for taribavirin in the treatment of hepatitis C, the continuing role of ribavirin or ...

Veteran-Owned Biotech Startup Company Charges Health Agency (NYSDOH) with Blackballing its Initiatives

... world-first U.S.-Egyptian collaborative study on hepatitis C and blood ozonation." This contracted study ... is overwhelmed with the highest prevalence of hepatitis C in the world. Furthermore, the fruits of this ... research would have immediately transferred to hepatitis C sufferers in the U.S., including the one ...

Pharmasset Reports Fiscal Second Quarter 2009 Financial Results

... for clevudine for the treatment of chronic hepatitis B infection, as well as increased preclinical development expenses for our second generation hepatitis C virus (HCV) product candidate, PSI-7851, and ... studies of clevudine for the treatment of chronic hepatitis B infection; On March 31, 2009, ...

Idenix Pharmaceuticals Reports First Quarter Financial Results

... 2009, data were presented from each of Idenix's hepatitis C programs at the annual meeting of the European ... Idenix's current focus is on the treatment of hepatitis C virus. For further information about Idenix, ... or commercialization activities in HIV or hepatitis C, or any potential pipeline candidates, ...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

... Phase 3 trial of Albuferon (R) in chronic hepatitis C; global marketing applications planned in fall ... of two pivotal trials of Albuferon in chronic hepatitis C, and we plan global marketing applications in ... Two Phase 3 Trials of Albuferon (R) in Chronic hepatitis C; Late-Breaker Results of Both Phase 3 Trials ...

GeneNews to conduct joint project funded by MYR 5 million grant from Malaysian government

... diagnostic tests for liver cancer, hepatitis B and nasopharyngeal cancer - TORONTO, ... blood-based diagnostic tests for liver cancer, hepatitis B and nasopharyngeal cancer based on their ... Dr. Haji Mohd Ismail Merican. "Liver cancer, hepatitis B - a liver disease that can result in liver ...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

... by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial ... Anadys is developing for the treatment of chronic hepatitis C virus (HCV) infection. Three Phase I trials, ... Non-Nucleoside Polymerase Inhibitor, In Chronic hepatitis C Patients," at the 44th Annual Meeting of the ...

Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver

... diseases, today reported data from its three hepatitis C development programs being presented this week ... focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, ... programs or commercialization activities in hepatitis C, or any potential pipeline candidate. Such ...

Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results

... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially ... to develop novel medicines in the areas of hepatitis C and oncology. Such forward-looking statements ...

Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables

... import and commercialize LG Life Sciences' hepatitis B vaccine, Euvax-B(TM), pursuant to the ... as awareness of the benefits of inoculations for hepatitis A and seasonal influenza increases across China. ... reflected increased sales of hepatitis A and hepatitis A&B vaccine in 2008. Net income for ...

Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results

... import and commercialize LG Life Sciences' hepatitis B vaccine, Euvax-B(TM), pursuant to the ... as awareness of the benefits of inoculations for hepatitis A and seasonal influenza increases across China. ... reflected increased sales of hepatitis A and hepatitis A&B vaccine in 2008. Net income for ...

Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008

... to commence in Q2. -- Launched the China hepatitis Internet Hospital ( http://www.zggbyy.com ... over-the-counter (OTC) treatment for hepatitis B. The increase in sales is also attributed to ... OTC product, and an estimated 120 million hepatitis B patients in China, we believe this product, in ...

Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference

... will present an overview of the company's three hepatitis C programs at the Canaccord Adams hepatitis C Conference on Tuesday, April 7 at 9:45 a.m. ET ... is on the treatment of infections caused by the hepatitis C virus. For further information about Idenix, ...

Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India

... of public health concern in that region, such as hepatitis E and Dengue fever. Cadila will contribute ... to India and the surrounding regions, including hepatitis E, chikungunya fever, dengue fever, and rabies. hepatitis E is a principal cause ...

Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry

... and its clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer. The corporate ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially ...

Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)

... announced that four abstracts from the company's hepatitis C antiviral discovery and development programs ... Oral presentation; Parallel session entitled: hepatitis C Virus Drug Development II; Session date: ... focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, ...

InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting

... the company's research programs related to the hepatitis C virus (HCV) have been accepted for presentation ... alfa-2a and Ribavirin in Patients with Chronic hepatitis C Virus (HCV). Incidence of ... A Mouse Model with Long Term Expression of hepatitis C Virus NS3/4A Protease for the Pharmacokinetic ...

AcroMetrix Announces the Release of OptiQuant-S Hepatitis C Virus (HCV) Panel

... with a critical component to fully optimize the hepatitis C molecular assays available in today's market. Viral hepatitis B and C now account for greater than 75% of all ... HCV represents our continued commitment to hepatitis C diagnostic testing," says Michael J. Eck, ...

Eiger BioPharmaceuticals Raises $7.1 Million 'A' Round

... targeted against NS4B, a specific region in the hepatitis C virus (HCV) protein, as well as progress lead ... and NS5A proteins will lead to uniquely effective hepatitis C treatments," said David Cory, President and CEO ... University and Director of the Center for hepatitis and Liver Tissue Engineering; he will serve as ...

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

... Market Nitazoxanide for the Treatment of Chronic hepatitis C TAMPA, Fla., Feb. 17 /PRNewswire/ -- ... of nitazoxanide as a treatment of chronic hepatitis C in Japan. Under the terms of the ... and marketing of treatments for chronic hepatitis C exemplified by their experience with Pegasys(R) ...

Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results

... polymerase inhibitor for the treatment of hepatitis C, and advanced the drug candidate into ... Idenix's current focus is on the treatment of hepatitis C virus. For further information about Idenix, ... or commercialization activities in HIV or hepatitis C, or any potential pipeline candidates, ...

Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes

... pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer. ... drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. ... in the first of two Phase 3 trials in chronic hepatitis C; results of the second Albuferon Phase 3 trial ...

Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C

... of nitazoxanide in the treatment of chronic hepatitis C virus (HCV) infection. In the phase II study in ... of Nitazoxanide for Treatment of Chronic hepatitis C," abstract FP052, was given by Emmet B. ... nitazoxanide tablet in patients with chronic hepatitis C genotype 1 later this year." In the Phase ...

Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets

... However, Insurance Coverage of hepatitis C Patients Is Skewed Towards Medicare and ... pharmaceutical and healthcare issues, finds that hepatitis C virus patient opportunity exists within many of ... have large bases of untreated patients. However, hepatitis C patients often lead high-risk lifestyles and ...

Pharmasset Reports Fiscal First Quarter 2009 Financial Results

... for clevudine for the treatment of chronic hepatitis B (HBV) infection, as well as increased ... of two oral antiviral molecules to treat hepatitis C virus (HCV) in the absence of interferon. The ... a leading franchise of nucleoside inhibitors for hepatitis C and B. Our plan is to provide updates ...

Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C

... with ribavirin in patients with genotypes 2 and 3 hepatitis C - ROCKVILLE, Md., Jan. 12 ... patients with genotypes 2 and 3 chronic hepatitis C. Albuferon is being developed by HGS and ... ) "Patients undergoing treatment for chronic hepatitis C often find it challenging to participate in ...

Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients

... 2b trial with R7128, a nucleoside inhibitor of hepatitis C (HCV), slated to initiate in the first quarter ... of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus ...

FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B & Hepatitis C

... to screen donated blood for HIV-1 Group M RNA, hepatitis C RNA and hepatitis B DNA in a single, automated assay. The test, ... HIV-1 Group M RNA, HIV-1 Group O RNA, HIV-2 RNA, hepatitis C Virus RNA ...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

... trial in patients with genotypes 2 and 3 chronic hepatitis C - - Patients receiving 900-mcg ... patients with genotypes 2 and 3 chronic hepatitis C (p=0.0086). Albinterferon alfa-2b is being ... interferon for the treatment of chronic hepatitis C, and we expect that global marketing ...

ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection

... to ANA598 for the treatment of chronic hepatitis C virus (HCV) infection. ANA598 is Anadys' investigational hepatitis C non-nucleoside polymerase inhibitor. Anadys is ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of ...

Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference

... three clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer. The presentation ... by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially ...
Other Contents
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/1/2015)... Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces the ... wallets is underway to early access pre-order customers. ... usage at retail outlets including Walmart, Target, AT&T, Dunkin, ... Wocket was accepted at all outlets and very easy ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
(Date:4/18/2015)... Canada (PRWEB) April 18, 2015 French ... emotions on food choices when he uttered, “Tell me ... you are.” Using food to cope with stress or ... by Queendom.com indicates otherwise. Data collected from ... genders fall victim to emotional eating, but for different ...
(Date:4/17/2015)... Rosetta Radiology is proud to now ... list of diagnostic imaging services. This solidifies them as ... Upper East Side of Manhattan. , The new imaging ... addition of PET-CT, combined with Rosetta’s state of the ... work with patients through several stages of the cancer ...
(Date:4/17/2015)... 17, 2015 Alcohol and Violence , ... notes that drinking and driving has been the focus ... same time, the link between alcohol and crime received ... and violence and sexual assault, and their relationship to ... NCADD, 5.3 million adults in America were drinking alcohol ...
(Date:4/17/2015)... From the day Dr. Todd Phillips founded ... organization has empowered young people to create meaningful change in ... fresh water and the Gospel to all of Liberia by ... 17 and 27, students, faculty and staff raised $21,000 through ... water and the Good News of Jesus. , During ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Representatives Jim ... Diagnoses and Treatment Act HR 1849 in congress on ... rates and treatment for patients with the genetic disease. ... the past, would be the first to create a ... appropriate treatment of hereditary hemorrhagic telangiectasia. This would effectively ...
Breaking Medicine News(10 mins):Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:House Representatives Introduce Bill to Fight Genetic Disease 2
Other TagsOther Tags